Events

Bio-IT World Conference w/ Mark Davies

The Emergence of the AI Augmented Drug Discoverer

Drug discovery is an immensely challenging problem. There are currently more than 9,000 untreated diseases with over 300 million people suffering from rare diseases for which we are unlikely to develop treatments any time soon. The drug discovery process still costs an average of $2.6 billion per drug. Even then, 30 to 50% of top selling drugs don't work for the patients in which they are prescribed for. We build technology in the service of science, specifically using AI to tackle this huge unmet need and to transform the traditional drug discovery process. In this talk Mark will discuss how integration of data is the foundation of which everything else is based, and describe our approach to using AI and human expertise to deliver validated unprecedented targets, and to enhance chemical drug design and precision medicine.

→ Register here

Mark Davies
SVP Informatics and Data at BenevolentAI

Mark is the SVP Informatics and Data at BenevolentAI. He has a background in molecular genetics, bioinformatics (BSc University of Sussex) and computer science (MSc Birkbeck College) and has over 15 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the London based biotechnology company Inpharmatica, where he was initially working on mining the output of the Human Genome Projects and eventually moved on to building Chemogenomics systems used by pharmaceutical companies, such as Bayer. Mark moved to the European Bioinformatics Institute (EMBL-EBI) as one of the founding members and technical lead for the ChEMBL resource - the largest open-source SAR database. Mark was also responsible for the successful transition of the SureChEMBL chemical patent system from Digital Science to the EMBL-EBI. Throughout his career Mark has published on how the use of biomedical data and technologies can improve the drug discovery process and enjoys identifying new opportunities this research space.

More Posts

You Might Also Like

News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022
News
BenevolentAI joins the World Economic Forum’s Global Innovators Community
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
Apr 21, 2022